AVITA Medical (RCEL) KOL event summary

Introduction and agenda

• Webinar and presentations focused on PermeaDerm clinical study results, real-world surgeon experiences, and economic and clinical outcomes as an alternative to allograft for wound temporization and closure.

• Agenda included clinical trial data review, study design, product positioning, workflow analysis, economic impact, case studies, and Q&A with burn surgeons.

KOL background and credentials

• Dr. Anju Saraswat: Assistant Professor of Surgery, Wake Forest University, and Burn Center Director at Atrium Health Wake Forest Baptist.

• Dr. Christina Sharon: Burn and acute care surgeon, Burn Director at Baton Rouge General, Louisiana.

• Panel included a Senior VP of Scientific & Medical Affairs and other experienced burn surgeons from major burn centers.

Market insights and analysis

• PermeaDerm is positioned as a modern, synthetic alternative to cadaveric allograft, addressing supply, storage, disease transmission, and workflow limitations.

• Surgeons highlighted ease of use, supply reliability, and workflow simplification as key advantages.

• PermeaDerm is an off-the-shelf product, providing logistical and workflow benefits for hospitals.